Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endosonography | 2 | 2021 | 97 | 1.040 |
Why?
|
| Liver Cirrhosis | 6 | 2010 | 241 | 0.790 |
Why?
|
| Pancreatitis, Chronic | 1 | 2021 | 11 | 0.700 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2021 | 76 | 0.680 |
Why?
|
| Pancreatitis | 1 | 2021 | 64 | 0.670 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2021 | 89 | 0.670 |
Why?
|
| Guideline Adherence | 1 | 2021 | 137 | 0.640 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 487 | 0.560 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2010 | 89 | 0.410 |
Why?
|
| Proton Pump Inhibitors | 2 | 2010 | 86 | 0.400 |
Why?
|
| Multidetector Computed Tomography | 1 | 2012 | 7 | 0.390 |
Why?
|
| Vascular Neoplasms | 1 | 2012 | 17 | 0.380 |
Why?
|
| Hypertension, Portal | 1 | 2010 | 22 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 214 | 0.320 |
Why?
|
| Gastroscopy | 1 | 2009 | 21 | 0.310 |
Why?
|
| Colonoscopy | 1 | 2009 | 108 | 0.290 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 405 | 0.290 |
Why?
|
| Fatty Liver | 5 | 2010 | 142 | 0.280 |
Why?
|
| Intestines | 1 | 2009 | 154 | 0.280 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2007 | 27 | 0.270 |
Why?
|
| Liver Failure, Acute | 1 | 2007 | 56 | 0.260 |
Why?
|
| Retrospective Studies | 7 | 2021 | 6578 | 0.250 |
Why?
|
| Pancreatic Ducts | 1 | 2025 | 13 | 0.240 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2025 | 7 | 0.240 |
Why?
|
| Obesity | 3 | 2010 | 1162 | 0.220 |
Why?
|
| Middle Aged | 8 | 2021 | 13014 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 1162 | 0.210 |
Why?
|
| Humans | 20 | 2025 | 52336 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 561 | 0.190 |
Why?
|
| Administration, Rectal | 1 | 2021 | 8 | 0.180 |
Why?
|
| Latin America | 1 | 2021 | 9 | 0.180 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 19 | 0.180 |
Why?
|
| Infection Control | 1 | 2021 | 46 | 0.170 |
Why?
|
| Epinephrine | 1 | 2021 | 93 | 0.170 |
Why?
|
| Health Care Surveys | 1 | 2021 | 177 | 0.170 |
Why?
|
| Acute Disease | 1 | 2021 | 374 | 0.160 |
Why?
|
| Adult | 6 | 2021 | 14139 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 122 | 0.160 |
Why?
|
| Aged | 6 | 2012 | 10109 | 0.160 |
Why?
|
| Risk Factors | 3 | 2021 | 3872 | 0.150 |
Why?
|
| Female | 8 | 2021 | 28105 | 0.140 |
Why?
|
| Liver Transplantation | 2 | 2011 | 165 | 0.140 |
Why?
|
| Pandemics | 1 | 2021 | 585 | 0.120 |
Why?
|
| Male | 6 | 2021 | 26696 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2021 | 2428 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 1021 | 0.110 |
Why?
|
| Adolescent | 4 | 2009 | 6692 | 0.100 |
Why?
|
| Factor VIIa | 1 | 2011 | 8 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 278 | 0.090 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 69 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 3391 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 48 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 61 | 0.080 |
Why?
|
| Liver | 3 | 2011 | 1159 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 879 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2010 | 98 | 0.080 |
Why?
|
| Bariatric Surgery | 1 | 2010 | 44 | 0.080 |
Why?
|
| Liver Abscess, Amebic | 1 | 2009 | 2 | 0.080 |
Why?
|
| Antiprotozoal Agents | 1 | 2009 | 9 | 0.080 |
Why?
|
| Radiography, Abdominal | 1 | 2009 | 25 | 0.080 |
Why?
|
| Metronidazole | 1 | 2009 | 28 | 0.080 |
Why?
|
| Suction | 1 | 2009 | 23 | 0.080 |
Why?
|
| Piperidines | 1 | 2009 | 97 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2009 | 43 | 0.080 |
Why?
|
| Drug Utilization Review | 1 | 2008 | 22 | 0.080 |
Why?
|
| Mexico | 1 | 2008 | 37 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2009 | 114 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 192 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 42 | 0.070 |
Why?
|
| Prevalence | 2 | 2008 | 1007 | 0.070 |
Why?
|
| Contrast Media | 1 | 2009 | 174 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 86 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 114 | 0.060 |
Why?
|
| Logistic Models | 1 | 2009 | 920 | 0.060 |
Why?
|
| Communicable Diseases | 1 | 2007 | 55 | 0.060 |
Why?
|
| Prognosis | 2 | 2010 | 2094 | 0.060 |
Why?
|
| Registries | 1 | 2008 | 580 | 0.060 |
Why?
|
| Drainage | 1 | 2025 | 87 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 940 | 0.060 |
Why?
|
| Insulin | 1 | 2006 | 481 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2011 | 5407 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 486 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2007 | 1532 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2010 | 594 | 0.050 |
Why?
|
| Stents | 1 | 2025 | 351 | 0.050 |
Why?
|
| United States | 1 | 2025 | 5182 | 0.030 |
Why?
|
| Publication Bias | 1 | 2011 | 14 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 491 | 0.020 |
Why?
|
| Cannabinoid Receptor Antagonists | 1 | 2009 | 16 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 468 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2008 | 26 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 94 | 0.020 |
Why?
|
| Population | 1 | 2007 | 8 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2009 | 138 | 0.020 |
Why?
|
| Lipids | 1 | 2008 | 157 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 555 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2008 | 106 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 21 | 0.020 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2006 | 11 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 636 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 96 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 569 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 84 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2008 | 583 | 0.020 |
Why?
|
| Metformin | 1 | 2006 | 76 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2008 | 471 | 0.020 |
Why?
|
| Child | 2 | 2008 | 7157 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2007 | 261 | 0.010 |
Why?
|
| Alcoholism | 1 | 2008 | 239 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 210 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2006 | 277 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2009 | 428 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 340 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 625 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 13523 | 0.010 |
Why?
|